

INDEPENDENT AUDITOR'S REPORT

To the Members of Suraksha Diagnostic Private Limited

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying Consolidated Financial Statements of Suraksha Diagnostic Private Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), which comprise the consolidated Balance Sheet as at March 31, 2022, and the Consolidated Statement of Profit and Loss, and the Consolidated Statement of Cash flows for the year then ended, and notes to the Consolidated Financial Statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the Consolidated Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Consolidated Financial Statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with Accounting Standards prescribed under section 133 of the Act read Companies (Accounts) Rules, 2014 as amended and other accounting principles generally accepted in India, of their consolidated state of affairs of the Group as at March 31, 2022, of Consolidated profit, and its Consolidated Cash Flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the Consolidated Financial Statements in India in terms of Code of Ethics issued by Institute of Chartered Accountant of India ("ICAI"), and the relevant provisions of the Act and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Consolidated Financial Statements and Auditor's Report Thereon

The Holding Company's Board of Directors is responsible for the other information. The other information comprises the Director's report but does not include the Consolidated Financial Statements and our auditor's report thereon. The Director's report is expected to be made available to us after the date of this auditor's report.

Our opinion on the Consolidated Financial Statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the Consolidated Financial Statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is



materially inconsistent with the Consolidated Financial Statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we read the Director's report if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance under SA 720 'The Auditor's responsibilities Relating to Other Information'.

Responsibilities of Management for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation and presentation of these Consolidated Financial Statements in term of the requirements of the Act that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Financial Statements by the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Financial Statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing ("SAs") will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Statements.

We give in "Annexure A" a detailed description of Auditor's responsibilities for Audit of the Consolidated Financial Statements.



Other Matters

We did not audit the financial statements of two subsidiaries, whose financial statements reflect total assets of Rs. 36.14 lacs as at March 31, 2022, total revenues of Rs. Nil and net cash outflows amounting to Rs.8.17 lacs for the year ended on that date, as considered in the Consolidated Financial Statements. These financial statements are unaudited and have been furnished to us by the Management and our opinion on the Consolidated Financial Statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, and our report in terms of sub-section (3) of Section 143 of the Act in so far as it relates to the aforesaid subsidiaries, is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Management, these financial statements are not material to the Group.

Our opinion on the Consolidated Financial Statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the financial statements certified by the Management.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, we report, to the extent applicable, that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid Consolidated Financial Statements.
 - b. In our opinion, proper books of account as required by law relating to preparation of the aforesaid Consolidated Financial Statements have been kept so far as it appears from our examination of those books and the reports of the other auditors.
 - c. The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, and the Consolidated Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the Consolidated Financial Statements.
 - d. In our opinion, the aforesaid Consolidated Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e. On the basis of the written representations received from the directors of the Holding Company as on March 31, 2022 taken on record by the Board of Directors of the Holding Company, none of the directors of the Holding Company is disqualified as on March 31, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f. With respect to the adequacy of internal financial controls with reference to financial statements of the Group and the operating effectiveness of such controls, refer to our separate report in "Annexure B".
 - g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:



- i. The Consolidated Financial Statements disclose the impact of pending litigations on the consolidated financial position of the Group - Refer Note 31 to the Consolidated Financial Statements.
 - ii. The Group did not have any material foreseeable losses on long-term contracts including derivative contracts.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company and its subsidiaries incorporated in India.
 - iv.
 - (1) The Management of the Holding Company have represented that, to the best of their knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Holding Company or any of such subsidiaries to or in any other person(s) or entity(ies), including foreign entities with the understanding, whether recorded in writing or otherwise, as on the date of this audit report, that such parties shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Holding Company or any of such subsidiaries ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - (2) The Management of the Holding Company have represented that, to the best of their knowledge and belief, no funds have been received by the Holding Company or any of such subsidiaries from any person(s) or entity(ies), including foreign entities with the understanding, whether recorded in writing or otherwise, as on the date of this audit report, that the Holding Company or any of such subsidiaries shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - (3) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances performed by us, and according to the information and explanations provided to us by the Management of the Holding company in this regard nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) as provided under (1) and (2) above, contain any material mis-statement.
 - v. The Holding Company has neither declared nor paid any dividend during the year. The subsidiaries are in the form of Limited Liability Partnership and hence the said provisions of the Act are not applicable on them.
2. In our opinion, according to information, explanations given to us, the provisions of Section 197 of the Act and the rules thereunder are not applicable to the Holding Company as it is a Private Limited Company. The subsidiaries are in the form of Limited Liability Partnership and hence the said provisions of the Act are not applicable on them.



MSKA & Associates

Chartered Accountants

3. With respect to the matters specified in clause (xxi) of paragraph 3 and paragraph 4 of the Companies (Auditor's Report) Order, 2020 ("CARO"/ "the Order") issued by the Central Government in terms of Section 143(11) of the Act, according to the information and explanations given to us, subsidiaries are in the form of Limited Liability Partnership and hence the said provisions of the Act are not applicable on them.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No. 105047W




Puneet Agarwal
Partner
Membership No. 064824
UDIN: 22064824AXOPVR1603

Place: Kolkata
Date: 30.09.2022

ANNEXURE A TO THE INDEPENDENT AUDITOR'S REPORT ON EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF SURAKSHA DIAGNOSTIC PRIVATE LIMITED

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Statements, including the disclosures, and whether the Consolidated Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the Consolidated Financial Statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the Consolidated Financial Statements of which we are the independent auditors. For the other entities included in the Consolidated Financial Statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.



MSKA & Associates

Chartered Accountants

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Financial Statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No. 105047W



Puneet Agarwal
Partner
Membership No. 064824
UDIN: 22064824AXOPVR1603

Place: Kolkata
Date: 30.09.2022

ANNEXURE B TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF SURAKSHA DIAGNOSTIC PRIVATE LIMITED

[Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report of even date to the Members of Suraksha Diagnostic Private Limited on the Consolidated Financial Statements for the year ended March 31, 2022]

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

Opinion

In conjunction with our audit of the Consolidated Financial Statements of the Company as of and for the year ended March 31, 2022, we have audited the internal financial controls with reference to Consolidated Financial Statements of Suraksha Diagnostic Private Limited (hereinafter referred to as "the Holding Company") as of that date.

In our opinion, and to the best of our information and according to the explanations given to us, the Holding Company, have, in all material respects, an adequate internal financial controls with reference to Consolidated Financial Statements and such internal financial controls with reference to Consolidated Financial Statements were operating effectively as at March 31, 2022, based on the internal control with reference to Consolidated Financial Statements criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India ("the ICAI").

Management's Responsibility for Internal Financial Controls

The Board of Directors of the Holding company are responsible for establishing and maintaining internal financial controls based on the internal control with reference to Consolidated Financial Statements criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Holding Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls with reference to Consolidated Financial Statements of the Holding company, based on our audit. We conducted our audit in accordance with the Guidance Note issued by the ICAI and the Standards on Auditing prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements



and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to Consolidated Financial Statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to Consolidated Financial Statements and their operating effectiveness. Our audit of internal financial controls with reference to Consolidated Financial Statements included obtaining an understanding of internal financial controls with reference to Consolidated Financial Statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to Consolidated Financial Statements of the Holding company.

Meaning of Internal Financial Controls With Reference to Consolidated Financial Statements

A company's internal financial control with reference to Consolidated Financial Statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Consolidated Financial Statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to Consolidated Financial Statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Consolidated Financial Statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the Consolidated Financial Statements.

Inherent Limitations of Internal Financial Controls With Reference to Consolidated Financial Statements

Because of the inherent limitations of internal financial controls with reference to Consolidated Financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to Consolidated Financial Statements to future periods are subject to the risk that the internal financial control with reference to Consolidated Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.



MSKA & Associates

Chartered Accountants

Other Matters

Our aforesaid reports under Section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls with reference to Consolidated Financial Statements insofar as it relates to the Group does not include the reports of two subsidiary entities as the said reporting on internal financial control is not applicable to those subsidiaries.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No. 105047W


Puneet Agarwal
Partner
Membership No. 064824
UDIN: 22064824AXOPVR1603



Place: Kolkata
Date: 30/09/2022

Particulars	Notes	As at 31-Mar-2022	As at 31-Mar-2021
Equity & Liabilities			
Shareholder's Fund			
Share Capital	3	852.86	852.86
Reserves & Surplus	4	14,144.46	11,769.49
Total Shareholder's Fund		14,997.32	12,622.35
Liabilities			
Non - Current Liabilities			
(a) Long-Term Borrowings	5	1,228.13	992.85
(b) Deferred Tax Liability (Net)	6	1,004.71	982.91
(c) Long-Term Provisions	7	31.14	11.01
Total Non-Current Liabilities		2,263.98	1,986.77
Current Liabilities			
(a) Short-Term Borrowings	8	673.81	650.21
(b) Trade Payables			
- Total outstanding dues of micro enterprises and small enterprises	9	4.29	4.63
- Total outstanding dues of creditors other than micro enterprises and small enterprises	9	1,383.03	1,255.77
(c) Other Current Liabilities	10	628.69	584.70
(d) Short-Term Provisions	11	120.60	0.30
Total Current Liabilities		2,810.42	2,495.61
Total Equity & Liabilities		20,071.72	17,104.73
Assets			
Non-Current Assets			
(a) Property, Plant and Equipment	12	11,755.30	11,691.31
(b) Other Intangible Assets	13	175.38	207.93
(c) Capital Work-in-Progress	12	123.51	0.86
(d) Intangible Assets Under Development	13	-	15.05
(e) Long-Term Loans & Advances	14	197.06	180.00
(f) Other Non-Current Assets	15	5,639.81	2,275.54
Total Non-Current Assets		17,891.06	14,370.69
Current Assets			
(a) Current Investments	16	-	541.18
(b) Inventories	17	622.53	444.50
(c) Trade Receivables	18	756.70	599.53
(d) Cash and Bank Balances			
- Cash and cash equivalents	19	257.47	293.21
- Other bank balances	19	25.00	149.83
(e) Short-Term Loans & Advances	20	518.96	705.79
Total Current Assets		2,180.66	2,734.04
Total Assets		20,071.72	17,104.73

Summary of Significant Accounting Policies 2

The accompanying notes are an integral part of the consolidated financial statements.


As per our report of even date
For M S K A & Associates
Chartered Accountants

ICAI Firm Registration No.:105047W


Puneet Agarwal
Partner
Membership No: 064824



Suraksha Diagnostic Private Limited
for and on behalf of the Board of Directors of


Dr. Somnath Chatterjee
Director
DIN: 00137075


Ritu Mittal
Director
DIN: 00165886

Place: Kolkata
Date: 30-09-2022



Suraksha Diagnostic Private Limited
CIN:U85110WB2005PTC102265
Statement of Profits and Loss for the year ended March 2022
(all amounts in INR Lacs, unless stated otherwise)

Particulars	Notes	For the year ended 31 March 2022	For the year ended 31 March 2021
Income			
I Revenue from Operations	21	22,319.25	14,000.57
II Other Income	22	230.34	137.60
III Total Income (I + II)		22,549.59	14,138.17
IV Expenses:			
Cost of Materials Consumed	23	6,040.49	2,600.96
Employee Benefits Expenses	24	3,413.94	2,492.09
Finance Costs	25	152.56	156.02
Depreciation and Amortisation Expenses	26	1,509.13	1,571.16
Other Expenses	27	8,114.23	6,680.56
V Total Expenses		19,230.35	13,500.79
VI Profit before Tax (III - V)		3,319.24	637.38
VII Tax Expenses :			
Current Tax (Net of MAT credit utilized amounting to Rs.21.28 lacs (Previous Year Rs.173.19 lacs)		922.47	133.17
Tax Relating to Earlier Years		-	5.46
Deferred Tax	6	21.80	(144.76)
		944.27	(6.13)
VIII Profit After Tax for the Year (VIII - IX)		2,374.97	643.51
Earnings per equity share (Nominal value of Rs 100/-)	28		
- Basic		344.20	93.26
- Diluted		278.47	75.45

The accompanying notes are an integral part of the consolidated financial statements.

As per our report of even date
For M S K A & Associates
Chartered Accountants
CAI Firm Registration No.: 105047W

Puneet Agarwal
Partner
Membership No: 064824

Place: Kolkata
Date: 30-09-2022



Suraksha Diagnostic Private Limited
for and on behalf of the Board of Directors of

Dr. Suman Chatterjee
Director
DIN: 00137075

Ritu Mittal
Director
DIN: 00165886



Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
A Cash Flow From Operating Activities		
Profit before Tax	3,319.24	637.38
Adjustment to reconcile profit before tax to net cash flows		
Depreciation and amortisation expense	1,509.13	1,571.16
Interest Income	(181.13)	(59.68)
Loss on Sale of Assets	141.48	245.03
Net gain on sale of current investments	(0.29)	(29.42)
Dividend income from mutual funds	(0.64)	(1.46)
Provision for doubtful debts	-	284.38
Liabilities / Provisions no longer required now Written back	(37.07)	(33.71)
Interest Expenses	152.56	156.01
Operating profit before working capital changes	4,903.28	2,769.69
Movement in working capital:		
(Increase)/Decrease in Inventory	(178.02)	100.12
(Increase)/Decrease in Trade Receivables	(116.26)	(284.39)
(Increase)/Decrease in Loans and Advances & Other Assets	(194.51)	(62.80)
Increase/(Decrease) in Trade Payables	123.08	(33.06)
Increase/(Decrease) in Other Liabilities	102.18	0.63
Increase/(Decrease) in Provision	37.98	11.31
Cash generated from operations	4,677.73	2,501.50
Income Tax Payments (including MAT Credit and net of refunds)	443.64	150.33
Net Cash generated from operating activities	A 4,234.09	2,351.17
B Cash Flows from Investing Activities		
Purchase of property, plant & equipment and intangibles assets including capital work in progress and capital advances	(1,924.89)	(1,540.06)
Payment of purchase consideration against acquisition of property, plant & equipment	-	(335.99)
Proceeds from sale of current investments	34.41	25.00
Purchase of current investments	541.47	557.78
Dividend income from Investments	-	(531.35)
Investment in fixed deposits (having original maturity of more than three months)	0.64	1.46
Interest Received	(3,211.30)	(1,007.35)
Net Cash used in investing activities	B (4,378.54)	(2,770.83)
C Cash flow from Financing Activities		
Increase in Term Loans for Medical Equipments & Car Loan	278.78	323.40
(Decrease)/Increase in Working Capital Term Loan	(19.90)	159.70
Interest Paid	(150.17)	(162.04)
Net Cash generated from Financing activities	C 108.71	321.06
Net increase/(decrease) in cash and cash equivalent	(A+B+C) (35.74)	(98.60)
Cash and Cash Equivalents at beginning of the year	293.21	391.81
Cash and Cash Equivalents at end of the year	257.47	293.21
Components of Cash and Cash Equivalent		
Cash in hand	30.45	54.89
Balance with Bank on Current Accounts	213.06	219.92
Prepaid Bank Balances	13.96	18.40
	257.47	293.21

Notes

- The above Cash Flow Statement has been prepared under the "Indirect Method" as stated in Accounting Standard 3 in 'Cash Flow Statement' prescribed under Companies Act, 2013
- Negative figures has been shown in bracket
- Previous Period's Figure have been regrouped/rearranged wherever necessary to confirm with current year's presentation

As per our report of even date
 For M S K A & Associates
 Chartered Accountants
 ICAI Firm Registration No. 105047W

 Puneet Agarwal
 Partner
 Membership No. 064824

For and on behalf of the Board of Directors of
 Suraksha Diagnostic Private Limited

Dr Somnath Chatterjee
 Director
 DIN: 00137075


 Ritu Mittal
 Director
 DIN: 00165886

Place: Kolkata
 Date: 30-09-2022



3 Share capital

Particulars	As at March 31, 2022	As at March 31, 2021
Authorised :		
12,20,000 equity shares of Rs. 100/- each (March 31, 2021: 12,20,000 equity shares of Rs.100/- each)	1,220.00	1,220.00
1,80,000 0.0001% Compulsorily Convertible Preference Shares of Rs. 100 each (March 31, 2021: 1,80,000 0.0001% Compulsorily Convertible Preference shares of Rs. 100/- each)	180.00	180.00
Total	1,400.00	1,400.00
Issued Subscribed and Fully Paid Up Shares :		
Equity Share Capital		
6,90,000 (Previous Year: 6,90,000) Equity Shares of Rs. 100/- each	690.00	690.00
Preference Share Capital		
1,62,859 (Previous Year: 1,62,859) 0.0001% Compulsory Convertible Cumulative Preference Share of Rs.100/-each	162.86	162.86
Total	852.86	852.86

(a) (i) Reconciliation of no. of equity shares & amount outstanding at the beginning and at the end of the year

Particulars	As at March 31, 2022		As at March 31, 2021	
	No. of Shares	Amount	No. of Shares	Amount
Equity Shares outstanding at the beginning of the year	6,90,000	690.00	6,90,000	690.00
Equity Shares Outstanding at the end of the year	6,90,000	690.00	6,90,000	690.00

(ii) Reconciliation of no. of preference shares outstanding at the beginning and at the end of the year

Particulars	As at March 31, 2022		As at March 31, 2021	
	No. of Shares	Amount	No. of Shares	Amount
0.0001% Compulsorily Convertible Preference Shares outstanding at the beginning of the year	1,62,859	162.86	1,62,859	162.86
0.0001% Compulsorily Convertible Preference Shares outstanding at the end of the year	1,62,859	162.86	1,62,859	162.86

(b) (i) Right, preferences and restrictions attached to equity shares

The Holding Company has only one class of equity share having face value of Rs.100/- each (March 31, 2021: Rs.100/- each). Each shareholder is entitled to one vote per share held. The Holding Company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the General Meeting. The above shareholding represent the legal ownership of shares.

In the event of liquidation of the Holding Company, the equity shareholders shall be entitled to receive remaining assets of the Holding Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders. Equity Shares held by OrbiMed Asia II Mauritius FDI Investments Limited in the Holding Company carry certain protective rights under the terms of the Shareholders Agreement.

(ii) Rights, preferences and restrictions attached to 0.0001% Compulsorily Convertible Preference Shares

Each 0.0001% Compulsorily Convertible Preference Shares has a face value of Rs 100/- (March 31, 2021: Rs.100/- each) and are convertible into 1(One) Equity Share of Rs 100 each at such time as required but mandatorily convertible after 19 years. The preference shares carry a dividend of 0.0001% per annum on the face value to be paid out of profits of the Holding Company. The preference share was issued on 27 March 2017.

(c) (i) Details of Equity Shares held by each Shareholder holding more than 5% of the Holding Company :

Name of Shareholder	As at March 31, 2022		As at March 31, 2021	
	No. of Shares held	% of holding	No. of Shares held	% of holding
Kishan Kumar Kejriwal	76,945	11.15%	76,945	11.15%
Dr. Somnath Chatterjee	66,000	9.57%	49,976	7.24%
Ritu Mittal	1,57,769	22.87%	1,21,661	17.63%
Satish Verma	1,33,689	19.38%	1,59,275	23.08%
Tinni Investment Limited	38,512	5.58%	38,512	5.58%
OrbiMed Asia II Mauritius FDI Investments Limited	1,34,587	19.51%	1,34,587	19.51%
Total	6,07,502	88.06%	5,80,956	84.19%

(ii) Details of 0.0001% Compulsorily Convertible Preference Shares held by each Shareholder holding more than 5% of the Holding Company :

Shareholders Name	As at 31-Mar-2022		As at 31-Mar-2021	
	No. of Shares held	% of holding	No. of Shares held	% of holding
OrbiMed Asia II Mauritius FDI Investments Limited	1,62,859	100.00%	1,62,859	100.00%
Total	1,62,859	100.00%	1,62,859	100.00%

(d) Disclosure of shareholding of promoters

Shareholders Name	As at 31-Mar-2022		As at 31-Mar-2021	
	No. of Shares held	% of holding	No. of Shares held	% of holding
Kishan Kumar Kejriwal	76,945	11.15%	76,945	11.15%
Dr. Somnath Chatterjee	66,000	9.57%	49,976	7.24%
Ritu Mittal	1,57,769	22.87%	1,21,661	17.63%
Satish Verma	1,33,689	19.38%	1,59,275	23.08%
Total	4,34,403	62.97%	4,07,857	59.10%

(e) Disclosure of % of change in shareholding of promoters

Shareholders Name	As at 31-Mar-2022		As at 31-Mar-2021	
	No. of Shares held	% of Change in Shareholding	No. of Shares held	% of Change in Shareholding
Dr. Somnath Chatterjee	66,000	2.32%	49,976	0.00%
Ritu Mittal	1,57,769	5.23%	1,21,661	7.69%
Satish Verma	1,33,689	(3.70%)	1,59,275	0.00%



4 Reserves & Surplus			
Particulars	As at March 31, 2022	As at March 31, 2021	
Securities Premium Account			
Balances at beginning of the year	4,837.09	4,837.09	
Add: Securities Premium credited on share issue	-	-	
Balances at end of the year	4,837.09	4,837.09	
Surplus in Statement of Profit and Loss :			
Balances at beginning of the year	6,932.40	6,288.89	
Add : Profit for the Year	2,374.97	643.51	
Less: Dividend to Preference Share holders*	(0.00)	(0.00)	
	9,307.37	6,932.40	
Total	14,144.46	11,769.49	

* Amount is below the rounding off norms adopted by the Group.

5 Long-Term Borrowings			
Particulars	As at March 31, 2022	As at March 31, 2021	
Secured			
Term Loan for Medical Equipment's: (Refer note below)			
From Banks	1,104.52	826.65	
Car Loans:			
From Banks	19.24	-	
Car Loans: (Refer note below)			
From a Financial Institution	15.19	26.39	
	1,138.95	853.04	
Unsecured			
Working Capital Term Loan:			
From Banks (Refer note below)	89.18	139.81	
	89.18	139.81	
Total	1,228.13	992.85	

Details of rate of interest, repayment and securities with respect to term loans for Medical Equipment's

The aforesaid term loans are secured against the hypothecation over Medical Equipment's against which such loans has been taken and Personal Guarantee of Directors. Such loans are repayable in equal monthly instalment over a period varying from 36 months to 68 months along with interest in the range of 8.55% to 9.80% p.a.

Details of rate of interest, repayment and securities with respect to Car Loans

The aforesaid term loans are secured against the hypothecation over Vehicle's against which such loans has been taken and Personal Guarantee of Directors. Such loans are repayable in equal monthly instalment over a period of 36 months along with interest in the range of 8.25% to 9.75% p.a.

Details of rate of interest, repayment and securities with respect to Working Capital Term Loan

The aforesaid working capital term loan is unsecured and is repayable in equal monthly instalment over a period of 48 months along with interest of 8.25% p.a.

6 Deferred Tax Liabilities (Net) - Non-Current			
Particulars	As at March 31, 2022	As at March 31, 2021	
Deferred Tax Liability			
Temporary differences in carrying cost of PPE & Intangibles assets between books of accounts & tax purpose	1,062.88	1,104.91	
Gross deferred tax liability	1,062.88	1,104.91	
Deferred Tax Asset			
Expenses allowable on payment, write off, etc.	47.55	118.71	
Provision for Employee Benefits	10.62	3.29	
Gross deferred tax asset	58.17	122.00	
Net Deferred Tax Liabilities	1,004.71	982.91	

7 Long-Term Provisions			
Particulars	As at March 31, 2022	As at March 31, 2021	
Provision for employee benefits			
Gratuity (Refer Note 30)	1.05	-	
Leave	30.09	11.01	
Total	31.14	11.01	

* Amount is below the rounding off norms adopted by the Group.



8 Short-Term Borrowings

Particulars	As at March 31, 2022	As at March 31, 2021
Secured - Current maturities of Long Term Borrowings (Refer Note 5)		
Term Loan for Medical Equipments:		
From Banks	608.93	616.72
Car Loans:		
From Banks	2.69	4.06
From Financial Institution	11.56	9.53
	623.18	630.31
Unsecured - Current maturities of Long Term Borrowings (Refer Note 5)		
Working Capital Term Loan:		
From Banks	50.63	19.90
	50.63	19.90
Total	673.81	650.21

10 Other Current Liabilities

Particulars	As at March 31, 2022	As at March 31, 2021
Security deposit received from collection centres	65.53	78.31
Capital creditors	23.20	83.73
Advance from Customers	65.87	2.45
Interest accrued but not due	7.37	4.97
Employee Benefits Payable	332.37	316.18
Statutory Dues payable	133.72	89.09
Other payables	0.63	9.97
Total Other current liabilities	628.69	584.70

11 Short-Term Provisions

Particulars	As at March 31, 2022	As at March 31, 2021
Provision for income tax (net of advance tax and tax deducted at source amounting to Rs. 1549.63 lacs (March 31 2021: Rs Nil))	114.21	-
Provision for Dividend of Preference Shares*	0.00	0.00
Provision for employee benefits		
Leave	6.39	0.30
Total	120.60	0.30

* Amount is below the rounding off norms adopted by the Group.



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Consolidated Financial Statements as at and for the year ended March 31, 2022

(all amounts in INR Lacs, unless stated otherwise)

9 Trade payables

Particulars	As at March 31, 2022	As at March 31, 2021
At amortised cost		
Total outstanding dues of micro enterprises and small enterprises	4.29	4.63
Total outstanding dues of creditors other than micro enterprises and small enterprises	1,383.03	1,255.77
Total	1,387.32	1,260.40

Based on the information available, the Group is having no outstanding dues and payments made to any supplier of goods and services beyond the specified period under Micro, Small and Medium Enterprises Development Act, 2006 [MSMED Act]. There is no interest payable or paid to any suppliers under the said Act.

9.1 Trade Payables Ageing Schedule - Based on the requirements of Amended Schedule III

Particulars	Outstanding as on March 31, 2022 from due date of payment						Total
	Unbilled Due	Not Due	Upto 1 Year	1-2 years	2-3 years	More than 3 years	
Total outstanding dues of micro enterprises and small enterprises	-	-	4.29	-	-	-	4.29
Total outstanding dues of creditors other than micro enterprises and small enterprises	68.38	985.91	242.28	86.46	-	-	1,383.03
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-	-
Total	68.38	985.91	246.57	86.46	-	-	1,387.32

Particulars	Outstanding as on March 31, 2021 from due date of payment						Total
	Unbilled Due	Not Due	Upto 1 Year	1-2 years	2-3 years	More than 3 years	
Total outstanding dues of micro enterprises and small enterprises	-	-	4.63	-	-	-	4.63
Total outstanding dues of creditors other than micro enterprises and small enterprises	68.18	756.90	178.91	251.78	-	-	1,255.77
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-	-
Total	68.18	756.90	183.54	251.78	-	-	1,260.40

